TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17022783

Group type: EXPERIMENTAL
Intervention: Single-fibre electromyography (SFEMG) with monopolar needle electrode (MNPE)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single-fibre electromyography (SFEMG) with single-fibre electrode (SFE)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Repetitive nerve stimulation (RNS) test
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single-fibre electromyography (SFEMG) with SFE
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Single-fibre electromyography (SFEMG) with MNPE
Number of subjects: 37
Study: 15265847

Group type: EXPERIMENTAL
Intervention: Pravastatin, 20 to 40 mg/d
Number of subjects: 214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 214
Study: 11084540

Group type: EXPERIMENTAL
Intervention: Continuous fetal pulse oximetry combined with electronic fetal monitoring (study group)
Number of subjects: 1010

Group type: COMPARATOR
Intervention: Electronic fetal heart rate monitoring alone (control group)
Number of subjects: 1010
Study: 9280211

Group type: EXPERIMENTAL
Intervention: 40 mmol/day potassium chloride for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8518017

Group type: COMPARATOR
Intervention: Goserelin acetate alone
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Goserelin acetate plus flutamide
Number of subjects: 373
Study: 3470953

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (Prepidil)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Artificial rupture of membranes combined with intravenous oxytocin
Number of subjects: 25
Study: 29159599

Group type: EXPERIMENTAL
Intervention: Laparoscopic mesh repair
Number of subjects: 102

Group type: COMPARATOR
Intervention: Laparoscopic sutured repair
Number of subjects: 102
Study: 27383186

Group type: EXPERIMENTAL
Intervention: mHealth intervention (android phone with application for reminders and educational messages)
Number of subjects: 933

Group type: COMPARATOR
Intervention: Control group (no mHealth intervention)
Number of subjects: 933
Study: 23839907

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 22
Study: 22434266

Group type: EXPERIMENTAL
Intervention: preSevo 1 (1.0-1.1 vol% sevoflurane with pre-exposure to 1 vol% sevoflurane)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: preSevo 2 (1.2-1.3 vol% sevoflurane with pre-exposure to 1 vol% sevoflurane)
Number of subjects: 64

Group type: COMPARATOR
Intervention: control 1 (1.0-1.1 vol% sevoflurane)
Number of subjects: 64

Group type: COMPARATOR
Intervention: control 2 (1.2-1.3 vol% sevoflurane)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 64
Study: 20163739

Group type: EXPERIMENTAL
Intervention: Physiotherapy program including exercise and manual therapy (individual sessions once a week for 10 weeks and daily home exercises)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Physiotherapy program including exercise and manual therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 18752443

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 3282

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine and Amodiaquine (SPAQ)
Number of subjects: 3282
Study: 15804467

Group type: EXPERIMENTAL
Intervention: UWCores
Number of subjects: 14
Study: 12877449

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 10967150

Group type: EXPERIMENTAL
Intervention: Regular walking during a golf game
Number of subjects: 110
Study: 8979525

Group type: EXPERIMENTAL
Intervention: Mailed-in questionnaire to study factors affecting initiation and quitting of smoking
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Presence of a smoker in the family
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quitting smoking
Number of subjects: 10
Study: 1437342

Group type: EXPERIMENTAL
Intervention: Bovine surfactant (50 mg/kg BW)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control (no surfactant)
Number of subjects: 69
Study: 3885671

Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate (5000 mg i.m. as a loading dose followed by 1000 mg every 2 weeks for one year)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Surgery plus intravaginal irradiation (Control group A)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Hydroxyprogesterone caproate
Number of subjects: 57
Study: 29738817

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) with open flap debridement (OFD)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Open flap debridement (OFD) alone
Number of subjects: 24
Study: 28033320

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (AA)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 23713493

Group type: EXPERIMENTAL
Intervention: HMW protein
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LMW protein
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Casein
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: HMW and LMW proteins
Number of subjects: 8
Study: 21840758

Group type: EXPERIMENTAL
Intervention: HCG triggering (Group A, n=30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Spontaneous ovulation (Group B, n=30)
Number of subjects: 60
Study: 19794988

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg intravenous ephedrine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study: 17283177

Group type: EXPERIMENTAL
Intervention: APEX1 51H variant
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: XRCC1 399Q variant
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Homozygotes at PARP1 loci (A284A and IVS13+118G>A)
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: PARP1 A284A
Number of subjects: 767
Study: 15080357

Group type: EXPERIMENTAL
Intervention: Ferric sulfate pulpotomy (FS)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Root canal therapy (RCT)
Number of subjects: 130
Study: 11465585

Group type: EXPERIMENTAL
Intervention: BIS-guided, model-based, closed-loop system for propofol administration
Number of subjects: 20

Group type: COMPARATOR
Intervention: Manual control of propofol administration using classical hemodynamic signs
Number of subjects: 20
Study: 9622403

Group type: EXPERIMENTAL
Intervention: 30-minute music therapy intervention
Number of subjects: 54

Group type: COMPARATOR
Intervention: Rest period (control group)
Number of subjects: 54
Study: 7878692

Group type: EXPERIMENTAL
Intervention: Erythromycin 500 mg orally three times a day for 6 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2458438

Group type: EXPERIMENTAL
Intervention: Higher-dose chemotherapy (600 mg/m2 cyclophosphamide and fluorouracil, 40 mg/m2 methotrexate)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Lower-dose chemotherapy (300 mg/m2 cyclophosphamide and fluorouracil, 20 mg/m2 methotrexate)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Higher-dose chemotherapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Lower-dose chemotherapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Crossover from lower-dose to higher-dose chemotherapy
Number of subjects: 133
Study: 29643011

Group type: EXPERIMENTAL
Intervention: Dolutegravir (50 mg oral once a day for 56 days)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (oral once a day for 56 days)
Number of subjects: 40
Study: 28858440

Group type: EXPERIMENTAL
Intervention: Vilazodone 40 mg/d
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 25851628

Group type: EXPERIMENTAL
Intervention: trastuzumab
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: lapatinib
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: trastuzumab and lapatinib combination
Number of subjects: 429
Study: 24180295

Group type: EXPERIMENTAL
Intervention: Structured and repeated multidisciplinary medication review supported by education and continuous evaluation.
Number of subjects: 360
Study: 20972646

Group type: EXPERIMENTAL
Intervention: Functional amino acid mixture (Aminotrofic®, Errekappa Euroterapici); 20% of estimated nitrogen requirements for 14 days
Number of subjects: 19

Group type: COMPARATOR
Intervention: Standard protein supplement; 20% of estimated nitrogen requirements for 14 days
Number of subjects: 19
Study: 18838923

Group type: EXPERIMENTAL
Intervention: Propofol/fentanyl
Number of subjects: 22

Group type: COMPARATOR
Intervention: Propofol/placebo
Number of subjects: 22
Study: 21446378

Group type: EXPERIMENTAL
Intervention: Amlodipine-based regimen
Number of subjects: 93

Group type: COMPARATOR
Intervention: Atenolol-based regimen
Number of subjects: 93
Study: 15932657

Group type: EXPERIMENTAL
Intervention: Early invasive strategy (coronary angiography performed within 48 hours)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Initially conservative strategy (coronary angiography performed after 48 hours)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Early invasive strategy with CABG
Number of subjects: 910
Study: 12354133

Group type: EXPERIMENTAL
Intervention: L‐T4 + I (iodized salt)
Number of subjects: 139

Group type: COMPARATOR
Intervention: L‐T4 alone
Number of subjects: 139
Study: 9834894

Group type: EXPERIMENTAL
Intervention: 0.05% mequitazine eyedrops
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.01% mequitazine eyedrops
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 40
Study: 8587426

Group type: EXPERIMENTAL
Intervention: ET-1 (nonselective agonist at ETA and ETB receptors)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ET-3 (ETB receptor agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sarafotoxin S6c (ETB receptor agonist)
Number of subjects: 0
Study: 2681488

Group type: EXPERIMENTAL
Intervention: Self-selected goals
Number of subjects: 20

Group type: COMPARATOR
Intervention: Assigned goals
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contingent gameplay conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Noncontingent gameplay conditions
Number of subjects: 20
Study: 333761

Group type: EXPERIMENTAL
Intervention: Live mumps vaccine from L-3 strain, single injection of 10(4)HAdU50 of mumps virus.
Number of subjects: 1507

Group type: EXPERIMENTAL
Intervention: Live mumps vaccine from L-3 strain.
Number of subjects: 1507

Group type: COMPARATOR
Intervention: Convalescents from mumps infection.
Number of subjects: 1507
Study: 29547081

Group type: EXPERIMENTAL
Intervention: Preoperative diffusion tensor imaging (DTI) and diffusion tensor tractography (DTT)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no DTI/DTT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Preoperative DTI/DTT
Number of subjects: 47
Study: 27505115

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Standard bupivacaine
Number of subjects: 57
Study: 24836868

Group type: EXPERIMENTAL
Intervention: Branded rifaximin (2×200mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Generic rifaximin (2×200mg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 24
Study: 22455828

Group type: EXPERIMENTAL
Intervention: Experimental intervention (multi-strategy intervention over 12 weeks)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 241
Study: 20526759

Group type: EXPERIMENTAL
Intervention: Aerobic training for 10 weeks
Number of subjects: 27
Study: 18672992

Group type: EXPERIMENTAL
Intervention: Tongue brushing and tooth brushing plus flossing
Number of subjects: 102

Group type: COMPARATOR
Intervention: Tongue brushing and tooth brushing
Number of subjects: 102
Study: 15683753

Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment
Number of subjects: 57
Study: 12854503

Group type: EXPERIMENTAL
Intervention: Low-dose radiation therapy (10 fractions of 2 Gy external beam)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 70
Study: 10535384

Group type: EXPERIMENTAL
Intervention: 200 microg octreotide per day for 6 months
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (unblinded)
Number of subjects: 27
Study: 8984868

Group type: EXPERIMENTAL
Intervention: Bougie First Group (gum elastic bougie)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stylet First Group (stylet)
Number of subjects: 100
Study: 1682683

Group type: EXPERIMENTAL
Intervention: Active antihypertensive therapy (three beta-blockers and one diuretic)
Number of subjects: 1627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1627
Study: 7007473

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 150 mg/day
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine 24 mg/day
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Hydroxyzine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Chlorpheniramine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Hydroxyzine and Chlorpheniramine
Number of subjects: 95
Study: 31362969

Group type: EXPERIMENTAL
Intervention: Antibiotic distribution
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 246
Study: 29448858

Group type: EXPERIMENTAL
Intervention: 3ABVD + involved-field (IF) low-dose (LD) irradiation (20 Gy) for GR1 patients with mediastinal mass or partial response after chemotherapy.
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 4 COPP/ABV for GR2 patients.
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: 6 COPP/ABV for GR3 patients.
Number of subjects: 560

Group type: COMPARATOR
Intervention: Response evaluated with conventional imaging (CI).
Number of subjects: 560
Study: 26147464

Group type: EXPERIMENTAL
Intervention: HES 6% 130/0.4
Number of subjects: 107

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 107
Study: 24374068

Group type: EXPERIMENTAL
Intervention: Micronutrient treatment for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Micronutrient treatment
Number of subjects: 64
Study: 22708638

Group type: COMPARATOR
Intervention: Standard lifestyle advice alone (control group)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Lifestyle advice combined with genetic or phenotypic risk estimate for T2D (intervention groups)
Number of subjects: 580
Study: 21162840

Group type: EXPERIMENTAL
Intervention: 10 µg CHO hepatitis B vaccine
Number of subjects: 642

Group type: EXPERIMENTAL
Intervention: 20 µg CHO hepatitis B vaccine
Number of subjects: 642
Study: 17852017

Group type: EXPERIMENTAL
Intervention: ALS Functional Rating Scale (ALSFRS‐R)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient-perceived clinical function
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Forced vital capacity
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Manual muscle testing (MMT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quality of life assessments
Number of subjects: 30
Study: 16061315

Group type: EXPERIMENTAL
Intervention: Locking palmar plating
Number of subjects: 53

Group type: COMPARATOR
Intervention: Non-locking palmar plating
Number of subjects: 53
Study: 12351591

Group type: EXPERIMENTAL
Intervention: Intensified CDE (cyclophosphamide 1,250 mg/m(2), doxorubicin 55 mg/m(2), etoposide 125 mg/m(2) with G-CSF 5 micro g/kg/d)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard CDE (cyclophosphamide 1,000 mg/m(2), doxorubicin 45 mg/m(2), etoposide 100 mg/m(2))
Number of subjects: 244
Study: 11773880

Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 9690802

Group type: EXPERIMENTAL
Intervention: Steroid therapy (specific dosage and duration not mentioned)
Number of subjects: 61
Study: 7710467

Group type: EXPERIMENTAL
Intervention: Immediate induction of labor (n = 265)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Expectant management (n = 175)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel (0.5 mg)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 440

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 440
Study: 2511611

Group type: EXPERIMENTAL
Intervention: Test formulation of phenoxymethylpenicillin suspension
Number of subjects: 319

Group type: COMPARATOR
Intervention: Standard formulation of phenoxymethylpenicillin suspension
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 319
Study: 323093

Group type: EXPERIMENTAL
Intervention: Calcium dobesilate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31238966

Group type: EXPERIMENTAL
Intervention: MS INFoRm website (intervention group)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care control group (control group)
Number of subjects: 200
Study: 29029337

Group type: COMPARATOR
Intervention: >90% IRS protection
Number of subjects: 565
Study: 25954938

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Escitalopram (10 to 20 mg) for 12 weeks
Number of subjects: 26
Study: 22900665

Group type: EXPERIMENTAL
Intervention: Visual Caries Dialogue (VCD) with comprehensive open discussion
Number of subjects: 230

Group type: COMPARATOR
Intervention: Traditional oral healthcare information (Control)
Number of subjects: 230
Study: 21810897

Group type: EXPERIMENTAL
Intervention: Captopril and atenolol as monotherapy
Number of subjects: 400
Study: 19074756

Group type: EXPERIMENTAL
Intervention: Home visitor education with GP participation in small group training
Number of subjects: 4034

Group type: EXPERIMENTAL
Intervention: Home visitor education
Number of subjects: 4034

Group type: EXPERIMENTAL
Intervention: Intervention municipalities
Number of subjects: 4034

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 4034
Study: 16919064

Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-headache controls
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Migraineurs and Non-headache controls
Number of subjects: 56
Study: 15646943

Group type: EXPERIMENTAL
Intervention: Three-headed toothbrush (group A)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional toothbrush (group B)
Number of subjects: 29
Study: 11282268

Group type: EXPERIMENTAL
Intervention: Intravenous pefloxacin (800 mg)
Number of subjects: 50
Study: 9080935

Group type: EXPERIMENTAL
Intervention: Knowledge of cigarette package warning labels
Number of subjects: 1747

Group type: COMPARATOR
Intervention: Knowledge of warning labels on cigarette advertisements
Number of subjects: 1747
Study: 8292723

Group type: EXPERIMENTAL
Intervention: 2 mg of vitamin K1 orally in addition to the usual warfarin dose (group B)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Discontinued warfarin for one day (group A)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups continued with their usual dose of warfarin after day 1
Number of subjects: 23
Study: 3100910

Group type: EXPERIMENTAL
Intervention: Dietary weight loss (n = 12)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Aerobic exercise (n = 14)
Number of subjects: 26
Study: 30582156

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) treatment, titrated from 2.5 to 20 mg/kg/d, with a maximum of 30 mg/kg/d based on response and tolerance.
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) treatment
Number of subjects: 264
Study: 28981901

Group type: EXPERIMENTAL
Intervention: Errorless learning plus ongoing supported employment
Number of subjects: 162

Group type: COMPARATOR
Intervention: Ongoing supported employment alone
Number of subjects: 162
Study: 26933876

Group type: EXPERIMENTAL
Intervention: Phendimetrazine (35, 70, and 105mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (10, 20, and 30mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 24393516

Group type: EXPERIMENTAL
Intervention: Quality development process
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 104
Study: 22446297

Group type: EXPERIMENTAL
Intervention: T-614 group 2 (25mg twice daily)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: MTX group (10 mg/week for the first 4 weeks and 15 mg/week for the subsequent 20 weeks)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: T-614 (50 μg/ml)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: T-614 (5 μg/ml or more)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: T-614 treatment
Number of subjects: 86
Study: 20173715

Group type: EXPERIMENTAL
Intervention: Short prophylactic therapy (2 grams of amoxicillin 1 hour before the procedure and 1 gram 6 hours after surgery)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Long postoperative regimen (1 gram of amoxicillin 6 hours after surgery followed by 1 gram every 8 hours for 4 days)
Number of subjects: 160
Study: 17610900

Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Open discectomy (OD)
Number of subjects: 23
Study: 16230754

Group type: EXPERIMENTAL
Intervention: Family involvement in care
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Staff encouragement
Number of subjects: 400
Study: 14664688

Group type: EXPERIMENTAL
Intervention: Fixed model approach for evaluating therapy studies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proposed approach by Crits-Christoph et al
Number of subjects: 0
Study: 10641419

Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment with emphasis on oral hygiene
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nifedipine administration
Number of subjects: 34
Study: 8889288

Group type: EXPERIMENTAL
Intervention: D-cycloserine 5 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: D-cycloserine 15 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo + molindone 150 mg p.o. q.d.
Number of subjects: 13